Profusa signs option to acquire diagnostics firm G3 Vision Labs
PFSA•Consideration terms
Upfront consideration includes 201,120 Profusa common shares and 52,903 shares of Series A non-voting convertible preferred stock, convertible 1,000-to-1 with approval.
If the option is exercised, sellers receive an additional 53,918 preferred shares; if not, G3 holders keep the upfront consideration.
Option agreement to acquire G3 Vision Labs
Profusa signed an option agreement to acquire diagnostics operator G3 Vision Labs, which estimates 2025 net revenue of about $111 million.
The option can be exercised up to delivery of specified financial information, then for 90 days, subject to conditions.
Key conditions include at least $30 million in financing commitments, refinancing or repayment of certain G3 debt, Nasdaq-related stockholder approval, and continued listing.
